Thu, Aug 28, 2014, 9:14 AM EDT - U.S. Markets open in 16 mins.

Recent

% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

  • riffissimo riffissimo Dec 20, 2012 8:37 AM Flag

    November 2012 Nature Ariticle - Pre-Clinical Link Between CRP and Rheumatoid Arthritis Symptoms

    A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and Humans

    Nicholas R Jones1, Melissa A Pegues1, Mark A McCrory1, Walter Singleton2, Claudette Bethune2, Brenda F Baker2, Daniel A Norris2, Rosanne M Crooke2, Mark J Graham2 and Alexander J Szalai1

    1Department of Medicine, Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, Alabama, USA
    2ISIS Pharmaceuticals, Inc., Carlsbad, California, USA

    Abstract
    Observational studies of patients with established rheumatoid arthritis (RA) document a positive correlation between C-reactive protein (CRP) blood concentration and worsening of RA symptoms, but whether this association is causal or not is not known. Using CRP transgenic mice (CRPTg) with collagen-induced arthritis (CIA; a rodent model of RA), we explored causality by testing if CRP lowering via treatment with antisense oligonucleotides (ASOs) targeting human CRP mRNA was efficacious and of clinical benefit. We found that in CRPtg with established CIA, ASO-mediated lowering of blood human CRP levels improved the clinical signs of arthritis. In addition, in healthy human volunteers the ASO was well tolerated and efficacious i.e., treatment achieved significant CRP lowering. ASOs targeting CRP should provide a specific and effective way to lower human CRP levels, which might be an effective therapy in patients with established RA.

 
ISIS
39.58+0.32(+0.81%)Aug 27 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.